Omeros Corporation (OMER)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Omeros Corporation.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 11.80 $ — 60% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 179.7% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 4
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.21 | -0.28 – -0.13 | 68 | -109.8% | 2 |
| 12/31/2027 | 0.38 | 0.07 – 0.69 | 143 | 285.4% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.27 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.54 | – | 0 | – | – | -29 | -29 |
| 2025: Q1 | -0.58 | – | 0 | -69.80 | -8,121.40 | -36 | -36 |
| 2025: Q2 | -0.43 | – | 0 | – | – | -22 | -22 |
| 2025: Q3 | -0.47 | – | 0 | – | – | -19 | -19 |
| 2025: Q4 | 1.36 | – | 0 | – | – | -40 | -40 |
| 2026: Q1 | 0.88 | – | 10 | 2,301.20 | 566.70 | -15 | -15 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 42 | -54 | -67 | -1.65 | -52 | -37 | 67 |
| 2017 | 65 | -44 | -53 | -1.17 | -36 | -3 | 116 |
| 2018 | 30 | -112 | -127 | -2.61 | -104 | 650 | 96 |
| 2019 | 112 | -63 | -84 | -1.71 | -60 | -109 | 137 |
| 2020 | 74 | -157 | -138 | -2.41 | -100 | -121 | 181 |
| 2021 | 91 | -174 | -111 | -1.79 | -110 | 24 | 419 |
| 2022 | 0 | -163 | 47 | 0.76 | -86 | 86 | 591 |
| 2023 | 0 | -165 | -118 | -1.88 | 75 | -25 | 378 |
| 2024 | 0 | -169 | -157 | -2.70 | -149 | -183 | 277 |
| 2025 | 0 | -123 | -3 | -0.05 | -116 | -121 | 326 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Omeros Corporation, ein biopharmazeutisches Unternehmen in der klinischen Phase, entdeckt, entwickelt und vermarktet niedermolekulare und Proteintherapeutika sowie Behandlungen für Orphan-Indikationen mit Fokus auf immunologische Erkrankungen. Der wichtigste Produktkandidat des Unternehmens ist Narsoplimab (OMS721/MASP-2) zur Behandlung von hä…
| Employees | 175 |
|---|---|
| Headquarters | Seattle, WA |
| Address | The Omeros Building, 98119 Seattle, United States |
| Phone | 206 676 5000 |
| Website | omeros.com |
| IPO Date | 8. Oct 2009 |
| ISIN | US6821431029 |
| Stock Split | 1:1.96 on 10/02/2009 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Gregory A. Demopulos M.D. | Co-Founder, Chairman, CEO & President | 1959 |
| David J. Borges | VP of Finance, Chief Accounting Officer & Treasurer | 1965 |
| Peter B. Cancelmo J.D. | VP, General Counsel & Corporate Secretary | 1979 |
| Pamela Pierce Palmer M.D., Ph.D. | Co-Founder | 1963 |
| George A. Gaitanaris M.D., Ph.D. | Chief Scientific Officer & VP of Science | 1957 |
| Peter W. Williams | Vice President of Human Resources | 1968 |
| Catherine A. Melfi Ph.D. | Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems | 1959 |
| David W. Ghesquiere | VP & Chief Business Development Officer | 1967 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.